This study will test how safe and effective cannabidiol (CBD) a chemical material from cannabis (marijuana) is in treating agitation in persons with Alzheimer's disease (AD). The study will have two phases in which participants will receive either the CBD medication first or a non-active treatment (i.e. placebo) first, and the order of these treatments will be reversed in the second phase. This study will also look at how CBD helps with overall behavioural symptoms and caregiver difficulties.
Eligibility Criteria
- Age Range: 55 years of age or older
- Have a diagnosis of Alzheimer's disease.
- Have agitation.
- Have a caregiver to accompany them to study visits and participate in the study.
What does the study involve?
- Number of contacts: 10+
- Format of study: Hybrid (mix of in-person and virtual visits)
- Compensation offered? Yes
Investigator(s): Dr. Sanjeev Kumar
Full Study Title: CAnnabidioL Medication Intervention Trial (CALM-IT)
Contact Information:
E-mail: CALM-IT.Study@camh.ca
REB number: 3878
REB Approval Expiry Date: February 13, 2027
PLEASE NOTE:
- Research staff cannot give medical advice over the phone or via email.
- If you have specific questions regarding your health care, please contact your family physician.
- We regret that not everyone screened for a study will be eligible to participate
- For more information about other treatment options for mental illness or addiction offered by CAMH, visit www.camh.ca or call 416-535-8501.